Company intelligence / Profile preview

Nickel

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Nickel Therapeutics is a precision oncology company focused on developing small molecule therapies for difficult-to-drug targets in cancer. Launched by Avalon BioVentures, the company utilizes a structure-based drug design platform to identify and optimize novel inhibitors for oncogenic drivers that have historically eluded therapeutic intervention. Their approach aims to provide highly selective treatments for patients with specific genetic mutations in solid tumors. Currently in the pre-clinical stage, Nickel Therapeutics is advancing a pipeline of proprietary programs designed to overcome resistance mechanisms and improve clinical outcomes in oncology.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nickel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nickel.

Explore the full profile